Teva Launches Generic HIV Drug

Teva Pharmaceutical Industries recently announced the launch of a generic version of atazanavir (Reyataz) capsules, according to a company press release.
Atazanir sulfate is a protease inhibitor approved as part of a combination of antiretroviral drugs for HIV-positive patients 6 years and older.
In clinical trials, approximately 20% of patients treated with atazanavir sulfate developed a rash. Teva reported that some patients also developed Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions, according to the press release.
Additionally, the most common adverse reactions include nausea, jaundice/scleral icterus, rash, headache, abdominal pain, vomiting, insomnia, peripheral neurologic symptoms, dizziness, myalgia, diarrhea, depression, and fever, according to the release.
Teva said that Rayataz had sales of $402 million in the United States, as indicated by October 2017 IMS data.
The launch of the generic drug may increase patient access to low-cost antiviral treatment and help prevent the spread of HIV, according to the release. 
“The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection,” said Brendan O’Grady, executive vice president, North America Commercial at Teva. “Antiviral medications continue to be a focus for Teva Generics, and this is an important addition to our portfolio.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.
Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.
Evolocumab (Repatha) consistently reduced low-density lipoprotein cholesterol in high-risk patients over time.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.